Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun A Fleming, Chun Yew Fong, Uma Borate, Meagan A Jacoby, Daniel Nowak, Maria R Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, Guillermo Garcia-Manero

Blood blood.2024025464.

https://doi.org/10.1182/blood.2024025464

Published: 2024

Includes: Supplemental data

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Journal Articles

Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

Guillermo Garcia-Manero, Olatoyosi Odenike, Shaun Fleming, Gail J. Roboz, Meagan Jacoby, Ilona Cunningham, Karl-Anton Kreuzer, Anoop K Enjeti, Maria R. Baer, Rachel Cook, Joseph Jurcic, Grace Ku, Ying Zhou, David Hoffman, Jalaja Potluri, Jacqueline S. Garcia

Blood (2023) 142 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2023-187102

Published: 2023

Journal Articles

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Blood (2023) 142 (Supplement 1): 620.

https://doi.org/10.1182/blood-2023-173509

Published: 2023

Journal Articles

Psychometric Validation and Meaningful Change Threshold Determination of EORTC QLQ-C30 Physical Functioning and Promis SF v1.0-Fatigue 7a Functional Domain in Patients with High-Risk Myelodysplastic Syndromes Treated with Venetoclax and Azacitidine

Roger M. Lyons, Brandon Foster, Adrian Jewett, Liu Liu, Rohini Sen, Cat N. Bui, Rajesh Kamalakar, Jalaja Potluri

Blood (2023) 142 (Supplement 1): 6472.

https://doi.org/10.1182/blood-2023-178011

Published: 2023

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong, Rachel Cook, Meagan Jacoby, Daniel Nowak, Brenda Chyla, Ying Zhou, Grace Ku, Jalaja Potluri, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 319.

https://doi.org/10.1182/blood-2023-189446

Published: 2023

Journal Articles

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J Thirman, Stanley Kotey, Jalaja Potluri, Mazaher Dhalla, Vinod Pullarkat

Blood (2023) 142 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2023-182045

Published: 2023

Journal Articles

Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J. Thirman, Melissa Montez, Yingyi Liu, John Katsetos, Jalaja Potluri, Catherine Miller, Vinod A. Pullarkat

Blood (2022) 140 (Supplement 1): 8993–8995.

https://doi.org/10.1182/blood-2022-158500

Published: 2022

Journal Articles

ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Recher, Andre C. Schuh, Sunil Babu, Monique Dail, Grace Ku, Yan Sun, Jalaja Potluri, Brenda Chyla, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 1441–1444.

https://doi.org/10.1182/blood-2022-169509

Published: 2022

Journal Articles

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Keith W. Pratz, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung-Soo Yoon, Ofir Wolach, Jun-Ho Jang, Su-Peng Yeh, Grace Ku, Ying Zhou, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 529–531.

https://doi.org/10.1182/blood-2022-158518

Published: 2022

Journal Articles

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Francesco Passamonti, James M. Foran, Anand Tandra, Valerio De Stefano, Maria Laura Fox, Ahmad H. Mattour, Mary Frances McMullin, Andrew Charles Perkins, Gabriela Rodríguez-Macias, Hassan Sibai, Qin Qin, Yan Sun, Jalaja Potluri, Jason Harb, Jonathan How

Blood (2022) 140 (Supplement 1): 583–585.

https://doi.org/10.1182/blood-2022-157949

Published: 2022

Journal Articles

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod A. Pullarkat, Brian A. Jonas, Christian Recher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo

Blood (2021) 138 (Supplement 1): 224.

https://doi.org/10.1182/blood-2021-145639

Published: 2021

Journal Articles

A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Kimberley Dilley, MD MPH, Jason Harb, PhD, Muhammad Jalaluddin, PhD, Jessica E. Hutti, PhD, Jalaja Potluri, MD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-139247

Published: 2020

Journal Articles

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

Brian A Jonas, MD PhD, Courtney D. Dinardo, MDMSc, Nicola Fracchiolla, Alexander Pristupa, MD, Kenichi Ishizawa, MD PhD, Jie Jin, MD PhD, Marina Konopleva, MD PhD, Yishai Ofran, Pau Montesinos, MD PhD, Tibor Kovacsovics, MD, Jun-Ho Jang, MD, Hagop M. Kantarjian, MD, Wan-Jen Hong, MD, Yinghui Duan, PhD, William Ainsworth, Jalaja Potluri, MD, Michael Werner, Anders Erik Svensson, MD, Keith W. Pratz, MD

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-134850

Published: 2020

Journal Articles

Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Subjects with Treatment-Naïve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Doerthe Eckert, MSc, Deanna Brackman, PhD, Rajeev Menon, PhD, Ahmed Hamed Salem, PhD FCP, Jalaja Potluri, MD, B. Douglas Smith, MD, Andrew H. Wei, John Hayslip, MD MSCR, Dale Miles, PhD, Sven Mensing, PhD, Sathej Gopalakrishnan, PhD, Jiuhong Zha, PhD

Blood (2020) 136 (Supplement 1): 52.

https://doi.org/10.1182/blood-2020-136425

Published: 2020

Journal Articles

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study Evaluating Navitoclax in Combination with Ruxolitinib in Patients with Myelofibrosis (TRANSFORM-1)

Jalaja Potluri, MD, Jason Harb, PhD, Abdullah A. Masud, PhD, Jessica E. Hutti, PhD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-139758

Published: 2020

Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

Daniel A. Pollyea, Courtney D. Dinardo, MDMSc, Martha L. Arellano, MD, Arnaud Pigneux, MD PhD, Walter Fiedler, MD, Marina Konopleva, MD PhD, David A Rizzieri, MD, B. Douglas Smith, MD, Atsushi Shinagawa, MD PhD, Roberto M. Lemoli, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Jean A Ridgeway, DNP, NP-C, Hagop M. Kantarjian, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-134736

Published: 2020

Journal Articles

The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis

Naveen Pemmaraju, MD, Jacqueline S. Garcia, MD, Jalaja Potluri, MD, Leanne Holes, BS, MBA,, Jason Harb, PhD, Paul Jung, PhD, Jessica E. Hutti, PhD, Josef T. Prchal, MD, Srdan Verstovsek, MD PhD, Claire Harrison, DM, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-136938

Published: 2020

Journal Articles

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-133912

Published: 2020

Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Marina Konopleva, MD PhD, Michael Thirman, MD, Keith W. Pratz, MD, Anthony G. Letai, MD PhD, Christian Recher, MD PhD, Vinod A. Pullarkat, MD, Hagop M. Kantarjian, MD, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Catherine Miller, PharmD, Courtney D. Dinardo, MDMSc, Andrew H. Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134100

Published: 2020

NARROW

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Psychometric Validation and Meaningful Change Threshold Determination of EORTC QLQ-C30 Physical Functioning and Promis SF v1.0-Fatigue 7a Functional Domain in Patients with High-Risk Myelodysplastic Syndromes Treated with Venetoclax and Azacitidine

Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A

ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Subjects with Treatment-Naïve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study Evaluating Navitoclax in Combination with Ruxolitinib in Patients with Myelofibrosis (TRANSFORM-1)

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only